
    
      Men and post- or induced menopausal women with ER[+] and/or PgR[+], HER2[- ] advanced BC,
      with centrally-confirmed PI3KCAMut who progressed to an aromatase inhibitor (AI) regimen.Men
      and post- or induced menopausal women with ER[+] and/or PgR[+], HER2[- ] advanced BC, with
      centrally-confirmed PI3KCAMut who progressed to an aromatase inhibitor (AI)
      regimen.Measurable or evaluable disease according to RECIST v.1.1 criteria.No prior treatment
      with fulvestrant or PI3K, AKT or mTOR inhibitors.

      No more than one prior line of chemotherapy for metastatic breast cancer (MBC). Eastern
      Cooperative Oncology Group (ECOG) Performance Status 0 - 1. No ongoing antidiabetic
      treatment.
    
  